CEO Corner

  1. Patients And Biopharma: Trusted Partners In Fighting Rare Diseases

    Partnerships between pharmaceutical companies and patient advocacy groups hold the key to closing the rare-disease treatment gap. Their mutual commitment to improving patient care is the foundation for collaborative innovation in rare-disease education and research.

  2. Building A Biotech with A Diversity Mindset

    A diverse workplace is critical to building a successful biotech company. When you’re leading an organization working to bring life-saving drugs to the market, every second matters, and you need to attract and retain the best talent to be successful.

  3. Leaders In Biotech: Raising Our Voices Beyond Industry’s Walls

    The CEO of Ovid Therapeutics, Jeremy Levin, feels no time has ever been better for biopharma leaders to speak out as part of their commitment to this industry.

  4. What Drug Developers Can Learn From Silicon Valley

    Though biotechnology may never be as fast and efficient as software, we can make innovation and development faster — through nothing more than a Silicon-Valley way of thinking.

  5. The Emergence Of New Gene Therapy Hubs

    With gene therapy, we are at the dawn of another era of potentially rapid growth in the sector. And companies planning for their futures will once again consider a range of factors in identifying the optimal locations for gene therapy research and production centers.

  6. How Moving Up Through The Ranks Can Shape A Biotech CEO

    All CEOs of small, publicly traded biotechs are required to wear many hats in the office every day. That’s why having a leader with a diverse background and experience in a variety of functional areas is an asset. Here we look at some of the various areas of expertise that can help create a more diverse C-suite executive.

  7. Successfully Transforming An Organization: An Active Approach

    Rich Daly, Chairman & CEO of Neuralstem, Inc., pens this month column and gives some enlightening anecdotes about what it takes to make "transformational" changes at a biopharma company.

  8. Collaborating To Stem The Tide Of Emerging Antimicrobial Resistance

    Jeffrey Stein, Ph.D., president and CEO of Cidara Therapeutics, discusses what needs to be done now by drug companies and healthcare providers alike to stem the tide of emerging antimicrobial resistance, including collaboration to address market barriers.

  9. The Biotech CEO — It’s Not For Everyone

    I’ve often described the challenge of developing new medicines as analogous to the difficulty of climbing the highest mountains on Earth. If one follows that analogy, then seeking to develop a new treatment for Alzheimer’s disease is like climbing K2, the second highest peak — in winter.

  10. The Case For A Healthcare Futures Market

    Now is the time to develop a novel financial instrument which will provide risk transfer, transparency, and more certainty. A futures market in healthcare is a product whose time has come.